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Background: The lysosomal storage disorder, Niemann Pick type C1 (NPC1), presents a variable phenotype
including neurovisceral and neurological symptoms. 2-Hydroxypropyl-ß-cyclodextrin (HPßCD)-based therapies are
presently the most promising route of intervention. While severe cerebellar dysfunction remains the main disabling
feature of NPC1, sensory functions including auditory and olfactory ones are also affected. Morphological and
functional anomalies of Npc1−/− mouse retina have also been observed, although the functional integrity of the
visual pathway from retina to visual cortex is still unsettled. We have addressed this issue by characterizing the
visual evoked potential (VEP) response of Npc1−/− mice and determining if/how HPßCD administration influences
the VEPs of both Npc1−/− and Npc1+/+ mice.
Methods: VEP elicited by a brief visual stimulus were recorded from the scalp overlying the visual cortex of adult
(PN, postnatal days 60, 75, 85 and 100) Npc1+/+ and Npc1−/− mice that had received repeated injections of either
HPßCD or plain vehicle. The first injection was given at PN4 and was followed by a second one at PN7 and thereafter
by weekly injections up to PN49. Cholesterol accumulation and myelin loss were finally assessed by filipin staining and
myelin basic protein immunohistochemistry, respectively.
Results and discussion: We have found that the transmission of visual signals from retina to visual cortex is negatively
influenced by the loss of Npc1 function. In fact, the VEP response of Npc1−/− mice displayed a highly significant increase
in the latency compared to that of Npc1+/+ mice. HPßCD administration fully rescued this defect and counteracted the
cholesterol accumulation in retinal ganglion cells and dorsal lateral geniculate nucleus neurons, as well as the myelin loss
in optic nerve fibers and axons projecting to the visual cortex observed in of Npc1−/− mice. By contrast, HPßCD
administration had no effect on the VEP response of Npc1+/+ mice, further strengthening the treatment efficacy.
Conclusions: This study pinpoints the analysis of VEP response as a potentially accurate and non-invasive approach to
assess neural activity and visual information processing in NPC1 patients, as well as for monitoring the progression of the
disease and assessing the efficacy of potential therapies.
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Niemann Pick type C1 (NPC1) disease is a rare, inherited
lysosomal storage disorder, having variable age of onset
and pathophysiological features. The most frequent pres-
entation of the disease is a child of either sex developing
coordination problems, dysarthria and hepatosplenome-
galy during early school-age years [1, 2]. The disease arises
from mutations affecting the function of the protein
encoded by the NPC1 gene that, in cooperation with
NPC2, mediates the intracellular trafficking of cholesterol
endocytosed via low-density lipoprotein receptors. In fact,
NPC1 and NPC2 proteins reside in the membrane and
lumen of late endosomes, respectively, and cooperate in
the outflow of unesterified cholesterol from late endo-
somes/lysosomes to endoplasmic reticulum and plasma
membrane, thereby enabling its incorporation in various
cellular compartments [3, 4]. Defects of either proteins
lead to the accumulation of endocytosed unesterified chol-
esterol and other lipids within lysosomes [5–7]. Approxi-
mately 95 % of NPC cases are due to mutations in the
NPC1 gene, and 5 % to mutations in NPC2 gene [2].
Prominent neurological signs of NPC1 disease in
humans, observed also in animal models as Npc1−/− mice
and cats, are cerebellar dysfunctions landmarked by the
progressive degeneration of cerebellar Purkinje cells [8, 9]
leading to ataxia [10]. However, other brain areas are also
involved in the disease, reducing the efficiency of the
processing of sensory information, including auditory,
olfactory and visual signals [11]. As indicated by studies in
the well established NPC1 mouse model, Npc1nih/nih
(Npc1−/−) [12], these defects are likely associated with
severe neuronal and glial damage in brain areas as the thal-
amus, which act as relay stations for sensory information
on the way to the cortex, whereas neurons of other brain
regions, including the cerebral cortex, appear less vulner-
able to NPC1-deficiency [13–15]. Within the thalamus of
Npc1−/− mouse, significant neuronal loss and marked gliosis
are detected in ventral postero-medial/lateral (VPM/VPL,
somatosensory), dorsal lateral geniculate (dLGN, visual)
and medial geniculate (MGN, auditory) nuclei as early as at
3 weeks of age [14]. Interestingly, hearing loss is among
neurological signs frequently associated with NPC1 disease
in our species [2, 16] and appears to rely on auditory brain-
stem neuropathology [17]. In fact, typical features of lyso-
somal cholesterol accumulation have been observed in the
cochlea, inferior colliculus and MGN of Npc1−/− mice [18],
which also display abnormal auditory brainstem responses
as early as at postnatal day 20 (PN20) [17].
Besides the auditory pathway, the cellular dysfunctions
of Npc1−/− mouse retina and dLGN suggest that the
visual pathway is also affected in NPC1 disease. Morpho-
logical and functional anomalies of the retina of these
mice were recently reported, showing age-related degener-
ation of photoreceptors and a number of anomalies inseveral cell types of the visual system, including increased
autophagy in retinal ganglion cell layer (GCL), electron-
dense inclusions in bipolar and Müller cells, abnormal
arborization of horizontal and amacrine cells, altered mye-
lination, dilated axons of the optic nerve [19] and reduced
amplitude of electroretinogram (ERG) responses [20]. How-
ever, studies investigating the functional integrity of the
visual pathway from retina to visual cortex are still lacking.
Visual evoked potentials (VEPs) are a well established
tool for assessing modifications of the visual pathway
integrity and visual cortex functioning during normal
aging and neurodegeneration in both humans and ani-
mal models [21–24]. Therefore, in this study we have
exploited VEP recording to investigate whether visual sig-
nal transmission from retina to visual cortex is impaired
in Npc1−/− mice. The preliminary evidence that the visual
pathway is actually defective in these mice prompted us to
also assess the rescuing efficacy of 2-hydroxypropyl-ß-
cyclodextrin (HPßCD), a drug representing the major
treatment currently studied in both patients and ani-
mal models of NPC1 disease.
The use of HPßCD was pioneered in a NPC1 mouse
model by Camargo et al. [25], but it was only when this
drug was administered earlier in life and at higher doses
that its therapeutic efficacy was widely appreciated [26–28].
In fact, extensive efforts using Npc1−/− mouse and cat
models have thoroughly demonstrated the ability of
HPßCD to mobilize intracellular cholesterol [29–34], lead-
ing to a phase I clinical trial that started in 2013 [35]. How-
ever, while HPßCD is considered generally safe, recent
studies have shown that it may cause dose-dependent hear-
ing loss in normal mice and in cats affected by NPC disease
[33, 36]. In light of this warning on the safety of HPßCD
treatment, the experimental design of this study included
the treatment of both Npc1+/+ and Npc1−/− littermates.
Our results show that the visual stimulus transmission
from retina to visual cortex is significantly delayed in
Npc1−/− mice compared to age-matched Npc1+/+ and
that HPßCD administration rescues this defect, having
no apparent effect on Npc1+/+ mice.
Methods
Animals and treatments
Npc1−/− mice are maintained on BALB/cJ background
and are derived from heterozygous matings. However,
instead of the expected 25 %, only 17 % of Npc1−/− are
weaned. Genotypes were identified at weaning by PCR
on tail DNA as described [12]. HPßCD administration
was performed by subcutaneous injection of either a
20 % solution (w/v; 4000 mg/Kg body weight) of HPßCD
(average degree of substitution of 0.67 of hydroxypropyl
groups per glucose unit, MW ~1369 Da, catalog number
H-107, Sigma Aldrich, Milan, Italy) in PBS, or plain PBS
as control. The treatment schedule was as follows: both
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subcutaneous injections at PN4 and PN7, followed by
weekly injections until PN49. Age-matched control mice
received plain PBS injections (sham animals). Within the
following 1–3 days (PN50-52) mice were chronically
implanted with electrodes. For HPßCD/sham adminis-
tration, pre-weaning PN4-PN21 pups were separated
from the mother, weighed, injected at the scruff of the
neck [26], monitored for complete absorption of the
injection bolus and finally returned to the home cage.
The entire injection procedure lasted approximately
15–20 min, giving each pup a similar treatment, in-
clusive of maternal separation, handling and injection.
A scheme summarizing the schedule of injection,
electrode implantation and VEP recording is shown
in (Additional file 1: Figure S1). HPßCD administra-
tion according to the schedule described above sig-
nificantly increased the life expectancy of Npc1−/−
mice (Additional file 2: Figure S2). Given that hetero-
zygous matings limited the availability of Npc1−/− and
Npc1+/+ pups, experimental groups were formed and
processed as follows: a first group of Npc1+/+ (n = 12)
and Npc1−/− (n = 12) age-matched mice that had not
received any kind of handling before electrode implant-
ation (naive mice) were subjected to VEP recordings at
PN75 (Fig. 1); a second group of Npc1+/+ and Npc1−/−
age-matched mice, either HPßCD-treated or sham (n = 13
in each experimental group), were subjected to VEP
recordings at PN60, PN75, PN85 and PN100, except for 5
mice of each experimental group that were sacrificed
immediately after the PN75 recording for histologicalFig. 1 VEP components of naïve PN75 Npc1+/+ and Npc1−/− mice.
Representative VEPs are shown in the figure. Note the increase in N1,
N2 and N3 latency and the reduction in amplitude displayed by Npc1
−/− compared to Npc1+/+ mice. N1, first negative peak; N2, second
negative peak; N3, third negative peakanalyses. In addition, the Npc1−/− mice were never
recorded at PN100 because they did not survive after
PN90-PN95. All mice were maintained in our animal
facility in accordance with Sapienza University guidelines
for the care and use of laboratory animals. Experimental
protocols and related procedures were approved by the
Italian Ministry of Public Health.
Visual Evoked Potential (VEP) recording
VEP experiments were performed according to pub-
lished procedures [37, 38]. Briefly, mice were anaesthe-
tized by intraperitoneal injection of a mixture of xylazine
(Rompun, Bayer AG, Leverkusen-Germania, 20 mg/Kg
i.p) and ketamine (Ketavet 100, Gellini Farmaceutici Spa,
Peschira Borromea-MI, 32 mg/Kg i.p.) and locally
injected with lidocaine (xylocaine 2 %, 0.1 ml under the
scalp) before the implantation of chronic electrodes.
Three epidural L-shaped monopolar stainless steel elec-
trodes were implanted (right anterior: 1.3 mm anterior
to bregma and 1.5 mm lateral to sagittal suture; right
and left posterior: 3 mm posterior to bregma and 2.5
lateral to sagittal suture), with the right posterior (active)
electrode position within the area of maximal visual
cortex acuity [39]. Electrophysiological recording started
1 week after electrode implantation. Each mouse, awake
and free to move, was dark-adapted for 20 min in an
anechoic testing cage placed in a dark, soundproofed
and electrically-shielded room before VEP recording.
Light flash-VEPs were elicited by a Grass-Instruments
PS22 photic stimulator (stimulus intensity 236.4 cd/m2/s;
stimulus rate 1 flash/s; stimulus duration 10 μsec) located
outside the sound-proofed cage to avoid acoustic contam-
ination from the strobe. To avoid possible interferences
due to circadian rhythm, VEPs were always recorded
between 09:00 and 12:00 a.m., EEG signals were amplified
through a DC-powered preamplifier with a gain of 1000×
and an analogic high-pass filter at 1 Hz and a low-pass
filter at 10 kHz. Acquisitions were performed at 2.5 kHz
sampling rate. An InstruNet A/D 16 bit conversion board
delivered signals to the acquisition system (Superscope
GW Instruments, Somerville, Massachusetts, USA, adapted
by Analysa, Cuneo, Italy) on a personal computer. Brain
activity and trigger were continuously acquired and saved
as raw data to be analyzed off-line. VEPs from a sequence
of 90 strobe light flash were averaged to obtain the final
waveform. After a pause of 5 min, the same mouse was
again stimulated by another series of 90 stimuli and this
procedure was repeated for a total of 6–8 times in the same
day. Registrations made anomalous by the occurrence of
artifacts and/or the insurgence of seizures, as previously
described in Npc1−/− mice [40], were discarded. VEP ampli-
tude and latency were measured after baseline removal. N1,
N2 and N3 latencies were calculated as the times elapsed
between the onset of first stimulus and the peak of the first,
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N1 amplitude was taken as the absolute value of the first
negative peak. Each mouse was used for repeated sessions
at increasing ages (PN58-62, PN73-77, PN83-87, PN98-
102), here for brevity indicated as PN60, PN75, PN85,
PN100, except for the Npc1−/− mice that, if not treated with
HPßCD, were not analyzed after PN85 because they usually
died at PN90-95 days, as previously reported [31].
Detection of intracellular cholesterol and myelin
PN75 Npc1+/+ and Npc1−/− mice, either injected with
HPßCD or sham according to the schedule of Additional
file 1: Figure S1, were anaesthetized by intraperitoneal in-
jection of a mixture of xylazine/ketamine (20–34 mg/kg
i.p) and then transcardially perfused with 4 % paraformal-
dehyde (PFA) in PBS. For filipin staining, brains, eyes and
optic nerves were removed, post-fixed overnight at 4 °C in
4 % PFA, cryoprotected with sucrose (30 % in PBS), em-
bedded in frozen section compound (FSC22 ClearR Frozen
Section Compound, Leica Biosystems, Milan, Italy) and
serially sectioned (slice thickness 10 μm) using a cryostat
(Leica CM 1900). Sagittal sections were mounted on adhe-
sive glass slides (X-tra glass slides, Leica Biosystems),
washed in PBS and post-fixed in cold acetone at −20 °C
for 10 min and then in 3 % PFA for 10 min. Sections were
incubated overnight at 4 °C in a buffer made of 0.1 M gly-
cine in PBS supplemented with 0.3 % BSA, stained with
filipin (10 μg/ml in PBS) for 3 h at room temperature and
finally mounted with buffered glycerol. For myelin basic
protein (MBP) detection, PFA-fixed tissues were dehy-
drated, embedded in Paraplast Tissue Embedding
Medium (Leica Biosystems) and serially sectioned (slice
thickness 8 μm). Sagittal sections were mounted on X-tra
Adhesive glass slides (Leica Biosystems), de-waxed with
xylene, re-hydrated and washed in PBS. Epitopes were
unmasked by heating sections twice (10 min each) in
0.1 M citric acid, pH 6.0, in a microwave oven. After
washing with PBS, sections were incubated overnight at
4 °C with a monoclonal anti-MBP antibody (Sigma-Aldrich,
Milano, Italy; 1:100 dilution in PBS), and then stained using
the rabbit Vectastain Elite ABC Kit (Vector Laboratories
Inc., Burlingame, CA, USA), followed by the DAB Peroxid-
ase Substrate Kit (Vector Laboratories Inc.) according to
manufacturer’s instructions. Epifluorescent images of fili-
pin/MBP staining (Additional file 3: Figure S3) were
obtained using a Zeiss Axioplan fluorescent microscope
equipped with Cool Snap K4 Photometrics camera or a
Sony nex-3 N mirrorless camera (Sony Europe Limited,
Milano, Italy). Images were processed using ImageJ NIH
software version 1.48v.
Gross histology and cell counts
The cytoarchitecture and cell number of visual cortex
and dLGN were determined by staining sagittal sectionsof PN75 Npc1+/+ and Npc1−/−, either sham or HPßCD-
treated, tissues with hematoxylin (Sigma-Aldrich) for
15 min and then eosin Y (0.3 % in ethanol 80 %; Sigma-
Aldrich) for 15 s. The counting of cell nuclei was per-
formed on three consecutive sagittal sections of at least
five mice/group, using the function “cell counter” of
ImageJ NIH software. Three region of interest (ROI,
400 μm2 each) were randomly selected in each field as
previously described [41], and histological observations
and evaluations were blindly and independently performed
by two investigators.
Statistics
Statistical analyses were performed using GraphPad
Prism version 5.0d (GraphPad, La Jolla, CA). Data were
tested for normality (Wilk-Shapiro’s test) and homosce-
dasticity (Levene’s test) and then analyzed by unpaired
two-tailed Student’s t test, one-way ANOVA, two-way
ANOVA for independent (group, genotype, treatment)
measures, and repeated measures one-way ANOVA
followed by Tukey’s HSD post-hoc test. P values smaller
than 0.05 were considered significant.
Results
An abnormal VEP indicates a decreased visual pathway
efficiency of Npc1−/− mice
VEPs consist of electrical potentials elicited by a brief
visual stimulus that are recorded from the scalp overly-
ing the visual cortex. Typically, VEP waveforms consist
of a sequence of voltage deflections named peaks, waves
or components. The shape of representative VEPs of
Npc1+/+ and Npc1−/− adult (PN75) mice is displayed in
Fig. 1. The three negative VEP components, N1, N2 and
N3, showed that the VEP response is strongly influenced
by Npc1 deficiency. In fact, N1-N3 VEP components of
Npc1−/− mice appeared with a delay of 1.5–2 msec
(latency) and displayed a reduced voltage amplitude
compared to those of Npc1+/+ mice. The values of
VEP latency and amplitude recorded in this experi-
ment are reported in Table 1.
VEP recordings of HPßCD-treated Npc1+/+ and Npc1−/− mice
display a specific rescue of VEP latency in Npc1−/− mice
Based on the defective VEP responses of Npc1−/− mice,
we settled to investigate the efficacy of HPßCD adminis-
tration in rescuing this defect. Studies aimed at charac-
terizing the ability of HPßCD to circumvent defective
cholesterol trafficking and disease severity in Npc1−/−
mice have so far exploited either a single injection at
PN7 [27] or repeated injections starting at PN7 or at
weaning [25, 28, 31], leading to the conclusion that earl-
ier injections resulted in a stronger efficacy. Therefore,
to boost the efficacy of HPßCD treatment, we designed
a treatment schedule consisting of two subsequent
Table 1 Effect of genotype on VEP latency and amplitude in
naive PN75 Npc1+/+ and Npc1−/− micea
Npc1+/+ (n = 12) Npc1−/− (n = 12) t (df )b pc
Latency, N1 27.59 ± 0.16d 28.98 ± 0.59 2.29 (22) 0.0396
Latency, N2 35.08 ± 0.62 37.35 ± 0.55 2.75 (22) 0.0118
Latency, N3 43.37 ± 0.81 44.70 ± 0.85 1.14 (22) 0.2778
Amplitude, N1 105.20 ± 13.67 22.00 ± 6.32 5.52 (22) 0.0001
aThe mice examined in this experiment did not receive any kind of
experimental manipulation before electrode implants and VEP recording
bDegree of freedom
cp was evaluated by unpaired two-tailed Student’s t test
dmean ± SEM
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blood brain barrier is completely formed [42] and when
cholesterol synthesis in the mouse brain reaches its
highest level [43], making it reasonable the expectation
that the neuronal import of glia-derived cholesterol isFig. 2 VEP components of naïve/sham PN75 Npc1+/+ and Npc1−/− mice. a
Note the different values of N1 peak latency and amplitude (arrows) depen
indicate the mean ± SEM of N1 latency and amplitude values obtained in t
of sham Npc1+/+ mice significantly decreased compared to that of naïve N
The amplitude of sham mice, either Npc1+/+ or Npc1−/−, did not significant
that of Npc1+/+ naïve mice. Asterisks indicate statistically significant differenmaximal. We also sought to continue injections after
PN7 by weekly injecting mice up to 7 weeks of age (see
Additional file 1: Figure S1).
Because of the novelty introduced in our protocol,
with particular reference to the early injection at PN4
shortly followed by an additional injection at PN7, we
sought to preliminarily evaluate the effect of plain PBS,
i.e. the vehicle of HPßCD administration (see Methods),
by comparing the VEP recordings of naïve Npc1+/+ and
Npc1−/− mice of Fig. 1 with representative VEP record-
ing of sham mice (Fig. 2a). Interestingly, the injections
of plain PBS significantly influenced the VEP response of
Npc1+/+ mice. In fact (Fig. 2b) these Npc1+/+ mice
(thereafter named “sham”) displayed a significantly
shortening of N1 latency (24.77 ± 0.32 msec) compared
to that of naive Npc1+/+ mice (27.59 ± 0.16 msec). By
contrast, the latency of PN75 sham Npc1−/− was similar
to that of naive Npc1−/− mice (28.16 ± 0.40 msec andRepresentative VEPs are shown in panel a (see Fig. 1 for description).
ding on experimental manipulation and/or genotype. b, c Histograms
he experimental groups indicated in the panels. Note that the latency
pc1+/+ mice, whereas sham and naïve Npc1−/− mice had similar latency.
ly differ from each other, but were significantly reduced compared to
ces among experimental groups (***, p < 0.001)
Fig. 3 VEP latency and amplitude in PN60, PN75, PN85 and PN100, either sham or HPßCD-treated, Npc1+/+ and Npc1−/− mice. a Histograms indicate
the mean ± SEM of N1, N2, and N3 latency values obtained in different experimental groups at increasing ages, as indicated in the panel. Note that
HPßCD fully rescued the latency increase observed in Npc1−/− mice, whereas it had no effect on Npc1+/+ mice. PN100 sham Npc1−/− mice are not
reported because these animals never survived beyond PN95, unless treated with HPßCD. b Effect of the age on N1 latency of various experimental
group. Note that the latency significantly increased with age in sham Npc1−/− mice, but not in Npc1+/+ mice, and that such increase was effectively
prevented by treatment with HPßCD (*, p < 0.05). c Histograms indicate the mean ± SEM of N1 amplitude values obtained in different experimental
groups at increasing ages, as indicated in the panel. Asterisks indicate statistically significant differences among experimental groups (*, p < 0.05; **,
p < 0.01; ***, p < 0.001)
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Fig. 4 HPßCD corrects the cholesterol storage defect of Npc1−/− mice.
Brain parasagittal sections of PN75 Npc1+/+ and Npc1−/− mice, either
sham or HPßCD-treated, were stained with filipin. Representative fields
(Additional file 3: Figure S3) of a primary visual cortex (V1), b dorsal
lateral geniculate nucleus (dLGN) and c retinal ganglion cells are shown
in the figure. Note that the cytoplasmic cholesterol accumulation
(arrowheads) is almost fully rescued by HPßCD. RPE: retinal pigment
ephitelium; OS: outer segments; ONL: outer nuclear layer; OPL: outer
plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL:
ganglion cell layer. Scale bars indicate 50 μm (a, b) and 25 μm (c)
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the VEP amplitudes of sham mice, either Npc1+/+ or
Npc1−/−, did not significantly differ from each other (N1:
32.36 ± 5.32 μV and 20.91 ± 2.22 μV, respectively; p <
0.05), in spite of the significant difference in N1 ampli-
tude values of naive Npc1+/+ and Npc1−/− mice (Fig. 2c).
The complete output of statistical analyses of VEP N1
latency and amplitude values is reported in (Additional
file 4: Table S1), whereas significant differences of post-
hoc comparisons are indicated by asterisks in Fig. 2.
In light of the observations reported above, subsequent
determinations of the effect of HPßCD on Npc1+/+ and
Npc1−/− mice, thereafter named “HPßCD”, were per-
formed using age-matched sham mice as controls. These
determinations provided a wealth of information that is
summarized as follows. First (Fig. 3a, b), the N1 latencies
of both sham and HPßCD-treated Npc1+/+ mice were
similar with each other (24.77 ± 0.32 msec and 24.82 ±
0.60 msec, respectively; p > 0.05), but significantly
shorter (p < 0.05) than that of Npc1+/+ naïve mice. Simi-
lar results were also obtained for N2 and N3 latencies.
We therefore concluded that HPßCD and PBS injections
had similar effects on Npc1+/+ mice, indicating a depend-
ence on the injection and/or maternal separation per se.
Second, HPßCD administration had a beneficial and
highly specific effect in normalizing the VEP latency of
Npc1−/− mice. Indeed, the latency of N1 wave appeared
significantly earlier in HPßCD-treated Npc1−/− compared
to that of Npc1−/− sham mice (24.39 ± 0.45 msec and
28.16 ± 0.40 msec, respectively; p < 0.05), indicating that
this effect depended on the HPßCD administration rather
than on the injection and/or maternal separation. More-
over, the N1 latency values of HPßCD-treated Npc1−/−
mice were similar to those of either HPßCD or sham
Npc1+/+ mice (24.82 ± 0.60 msec and 24.77 ± 0.32 msec,
respectively; p > 0.05), indicating that HPßCD effect-
ively rescued cellular/molecular substrates underlying
the Npc1−/− deficiency. Similar results were also ob-
tained for N2 and N3 latencies. It is also interesting to
note that the N1 latency of sham Npc1+/+, HPßCD-
treated Npc1+/+ and HPßCD-treated Npc1−/− mice did not
increase from PN60 to PN85, whereas it significantly in-
creased in sham Npc1−/− mice (Fig. 2b), suggesting that
HPßCD effectively prevented the visual system impairment
that Npc1−/− mice undergo with aging. The statistical ana-
lysis of this panel is reported in (Additional file 5: Table S2).
In contrast to latency, VEP amplitude (Fig. 3c) was not
significantly affected by HPßCD in both Npc1−/− and
Npc1+/+ mice, indicating that the observed variations in
this parameter were fully independent on the drug. The
complete output of statistical analyses of VEP N1, N2,
N3 latency and N1 amplitude values recorded at PN60,
PN75, PN85, PN100 are reported in (Additional file 6:
Table S3, Additional file 7: Table S4), whereas significantdifferences of post-hoc comparisons are indicated by
asterisks in Fig. 3.
HPßCD rescues the abnormal cholesterol accumulation of
Npc1−/− mice
To verify whether HPßCD not only normalized the VEP
latency of Npc1−/− mice, but also rescued the abnormal
cellular features typical of the disease, we visualized intra-
cellular cholesterol accumulation by filipin staining on
brain slices of PN75 sham or HPBCD-treated, Npc1+/+
and Npc1−/− mice. We first focused this analysis on visual
cortex and thalamic dLGN (representing the only relay
station for visual information on its way from retina to
visual cortex) [44, 45]. Interestingly, the HPßCD adminis-
tration almost completely eliminated the filipin-stained
cholesterol deposits present in the visual cortex and
dLGN of Npc1−/− sham mice (Fig. 4a, b). Similar features
were also observed in retinal ganglion cells (Fig. 4c),
whereas HPßCD administration did not have any effect
on Npc1+/+ mice (Fig. 4a–c).
HPßCD rescues the myelin loss of Npc1−/− mice
Both NPC patients and Npc1−/− mice display a promin-
ent dysmyelination, although the mechanism(s) that
Fig. 5 (See legend on next page.)
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Fig. 5 HPßCD counteracts the myelin loss of Npc1−/− mice. Brain sections of PN75, either sham or HPßCD-treated, Npc1+/+ and Npc1−/− mice were
immunostained with anti-myelin basic protein antibody (brown). Representative fields (see Additional file 3: Figure S3) of parasagittal sections of a
primary visual cortex b primary somatosensory cortex, and c transversal sections of optic nerve are shown in the figure. The robust myelin reduction of
Npc1−/− mice was partially rescued by HPßCD administration. I–VI: cortical layers; fmj: forceps major corpus callosum; CPu: caudate putamen (striatum). Scale
bars indicate 50 μm (a, b) and 6 μm (c)
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not fully understood. In fact, both neuronal and/or
oligodendrocyte deficiency of Npc1 protein can severely
affect the synthesis of myelin at early postnatal days,
resulting in myelin loss with aging [46]. To assess
whether a myelin deficit was a putative cause of the
increase in the VEP latency of Npc1−/− mice, brain
sections of PN75 sham or HPßCD-treated Npc1+/+ and
Npc1−/− mice were immunostained with an antibody
directed against the myelin basic protein (MBP) (Fig. 5).
Parasagittal sections encompassing both somatosensory
and primary visual cortices (Fig. 5a, b) of Npc1+/+
showed a similar abundance of myelinated fibers in the
regions of both sham and HPßCD-treated Npc1+/+,
whereas myelinated fibers were below the level of detec-
tion in Npc1−/− mice. MBP immunostainig of optic nerve
sections of Npc1−/− mice also showed a similar pattern of
myelin reduction, which was partially rescued by HPßCD
administration (Fig. 5c). Moreover, gross histology ana-
lyses showed a significant reduction of cellularity in both
visual cortex and dLGN (Fig. 6), making it reasonable that
a neuronal loss contributed to the visual cortex myelin re-
duction of Npc1−/− mice. The cytoarchitecture of visual
cortex appeared also disorganized in Npc1−/− mice,
whereas both cellularity and cytoarchitecture were nor-
malized by the HPßCD administration (Fig. 6a).
Discussion
The rationale for undertaking this study was grounded on
accumulating evidence that there is severe neuronal and
glial damage in thalamocortical areas of Npc1−/− mice
[15, 47], as well as defective myelin formation and mainten-
ance associated with Npc1 functional deficiency [46, 48].
These abnormalities are likely associated with an impair-
ment of various sensory pathways, as already indicated by
the deficit of auditory [11, 49] and olfactory [50] systems in
Npc1−/− mice and of multisensory processing in NPC pa-
tients [51]. As for the visual system of Npc1−/− mice, retinal
cellular and functional defects were recently described [19,
20], but the functional integrity of their visual pathway has
not been investigated yet. Now addressing this issue, we re-
port that the transmission of visual stimuli from retina to
visual cortex is strongly influenced by the lack of Npc1 func-
tion. In fact, compared to naïve Npc1+/+ mice, naïve Npc1
−/− mice displayed a significant increase in the latency and a
dramatic decrease in the amplitude of their N1-N3 VEP
components, likely due to gross histological and cellularalterations of the visual system of these mice, including
cholesterol accumulation, reduced cellularity, and a high
level of demyelinization along the entire visual stimulus itin-
erary, from retina to visual cortex (present data, [46, 52]).
Different cellular/functional mechanism(s) are likely
underlying the VEP features of sham Npc1+/+ and Npc1−/−
mice. In the case of Npc1+/+ mice, in fact, the postnatal in-
jection of plain PBS elicited dramatic VEP changes during
adulthood resulting in a significant decrease of both la-
tency and amplitude. These modifications are likely to re-
flect the ability of normal mouse brain to modify its
structure and function in response to a week and transi-
tory stress(es) (as the interscapular injections, transient
body constriction and brief maternal separation per-
formed in our experiments) during early postnatal life.
Among these putative stressors, maternal separation
should be ruled out because its duration in present ex-
periments (20 min) was much shorter than the 3 h dur-
ation required for a permanent negative effect during
adulthood in the mouse [53]. In contrast, it is well
documented that the administration of short-lasting
stresses during infancy elicits an opposite effect, increas-
ing adult brain resilience to stress in both mice and
humans [54]. In line with this view, the significant de-
crease in VEP latency and amplitude of sham Npc1+/+
mice suggests that, among other possibilities, the early
postnatal stress improved the adult visual pathway effi-
ciency and specialization (decrease in latency) and
reduced the overall number of stimulus-locked oscillations
(decrease in amplitude) [55].
While the VEP response of sham Npc1+/+ mice is appar-
ently modified by the postnatal stress, this is likely not true
for sham Npc1−/− mice. In this case, in fact, the injection
protocol did not elicit any significant effect on both VEP
latency and amplitude, suggesting these mice were actually
unable to respond to postnatal stress as wild-type mice did.
We favor the hypothesis that such ability was missing in
Npc1−/− mice because of the severe structural and/or func-
tional disorganization of their visual system, including eye,
optic nerve, dLGN and cortex. It is also worth to note that,
although the small VEP amplitude of naïve/sham Npc1−/−
mice was statistically similar to that of sham Npc1+/+ mice,
it likely was very different in nature. In fact Npc1−/− sham
mice also displayed an abnormally high value of VEP
latency, in line with their altered neuroanatomical features.
The latency value of HPßCD-treated Npc1+/+ mice
was similar to that of Npc1+/+ sham mice, indicating
Fig. 6 HPßCD rescues the reduced cell number of Npc1−/− mice. Brain
sections of PN75, either sham or HPßCD-treated, Npc1+/+ and Npc1−/−
mice were stained with haematoxylin and eosin. Representative fields
(see Additional file 3: Figure S3) of a primary visual cortex and b dorsal
lateral geniculate nucleus (dLGN) are shown in the figure. c Histograms
indicate cell densities (mean ± SEM) determined on 5 randomly
selected 400 μm2 regions of primary visual cortex (V1) and lateral
geniculate nucleus (dLGN). Asterisk indicates a significant difference (*,
p < 0.05). fmj: forceps major corpus callosum; I-VI cortical layer. Scale
bars indicate 50 μm (a, b)
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and sham Npc1+/+ mice displayed an approximately 3 msec
reduction of N1 latency compared to that of Npc1+/+ naivemice, leading to the conclusion that the latency decrease of
Npc1+/+ sham and HPßCD-treated mice is a consequence
of the stress elicited by pup manipulation associated with
the injection per se. This conclusion is in agreement with a
previous study showing a similar (3–3.5 msec) reduction in
VEP latency of adult mice that had received repeated saline
injections and manipulation-elicited stress during early
postnatal life [56].
The response of Npc1−/− mice to HPßCD administra-
tion was completely different. In fact the drug rescued
the increased VEP latency of Npc1−/− mice, eliciting
latency values that nicely approximated those of both
sham and HPßCD-treated Npc1+/+ mice. This beneficial
effect was therefore associated with the drug rather than
with the injection/manipulation per se.
Both sham and HPßCD treatments did not determine
any significant difference between the amplitudes of
Npc1+/+ and Npc1−/− mice. High variability and low
consistency are frequently observed in repeated ampli-
tude recordings of the same animal (not shown), likely
because this component is greatly influenced by the
background level of ongoing cortical activity [57, 58].
For this reason, latency is generally considered a more
robust and reliable indicator of the visual pathway integ-
rity [52] compared to amplitude. This is particularly true
for a mouse model presenting demyelination as the
Npc1−/− mouse [46], in which the latency delay we
report in this study likely reflects, among other cellular/
histological alterations, the high level of demyelination
along the visual stimulus itinerary [52].
By unveiling the different VEP response of sham and
HPßCD-treated Npc1+/+ and Npc1−/− mice, our results
further strengthen the specific effect of HPßCD treat-
ment in normalizing Npc1−/− brain structural/functional
organization, including that of visual pathway. Accordingly,
we show that cholesterol accumulation in retinal ganglion
cells, in dLGN neurons and in visual cortex are largely
rescued by the HPßCD administration, which also counter-
acts the robust myelin reduction in optic nerve fibers and
axons projecting to the visual cortex of Npc1−/− mice.
Conclusions
The results of this study based on VEP analysis expand
recent observations on the presence of severe neuronal
and glial damage in brain areas as the thalamus, correl-
ating these features to the impairment of visual stimulus
transmission from retina to visual cortex. They also
provide an additional insight on the effectiveness and
safety of HPßCD administration. In light of these
findings, VEP analysis appears as a putatively accurate
and non-invasive tool to monitor neural activity and
sensory processing in NPC1 patients, as well as to moni-
tor disease progression and to assess the efficacy of
potential therapies.
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naive Npc1−/−, 91.3 ± 1.3; sham Npc1−/−, 87.8 ± 0.9; HPβCD Npc1−/−,
145 ± 3.0. (JPEG 2830 kb)
Additional file 3: Figure S3. Circles indicate the brain areas selected for
histological analyses. 1, primary visual cortex; 2, dorso lateral geniculate
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nucleus; CPu, caudate putamen; cc, corpus callosum; LV, lateral ventricle; S1,
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